3D Tumor Cell Culture Models

90% of drugs that seem promising in vivo ultimately fail in the clinic. Collecting more predictive, translational data that represents a therapy’s interaction with the human immune system and tumor microenvironment (TME) is essential to predicting clinical success, and yet not all programs take this approach.

Optimal Translation: 3D Tumor Models

In conjunction with our drug sensitivity and molecular characterization data, our 3D tumor models allow you to evaluate the potency of your compound compared to standard-of-care drugs. Created using our proprietary patient-derived xenograft (PDX Model) explants or cell line-derived xenografts (CDX models) the 3D tumor models allow you to identify the most promising drug candidates, tumor histotypes, and molecular subtypes for further testing.

Our 3D cell culture models can support you oncology and immuno-oncology drug development and includes a range of immune cell-mediated tumor killing assays.

Our 3D tumor models and services include:

  • Clonogenic Assay 3D tumor models
  • Engineered hydrogel 3D tumor models
  • Combination studies
  • Integration with in vitro and in vivo PDX models


Engineered Hydrogel 3D Tumor Models

Through our partnership with Cypre, you now have access to Cypre's 3D tumor models that use their 3D hydrogel patterning technology – Symphony® and VersaGel® – to predict therapeutic efficacy in an accurate model of the tumor microenvironment.

Hydrogel 3D Tumor Models

Human cells are isolated and introduced into the Falcon-X 3D tumor model platform, including PDX, fibroblasts and PBMCs. The resulting hydrogel 3D model is analyzed by high content imaging.

Figure 2: Schematic of Cypre’s 3D Tumor Models Platform.

Cypre’s proprietary 3D tumor models platform,  is a high content analysis screening option for cancer immunotherapy and targeted therapy. Utilizing Cypre’s patented 3D hydrogel technology and proprietary methods that synergize with the breadth and depth of our PDX tumor model collection, the platform recreates the tumor microenvironment and enables predictive screening of innovative (immuno)-oncology compounds.

This 3D assay platform offers unique advantages for drug development studies:

  • Immune cell infiltration through matrix
  • Co-culture of stromal and immune cells beyond tumor cells
  • Mimicking cold and hot tumors by combination of different cell types
  • Modulation of invasiveness by matrix composition
  • Optically clear gel for rapid image analysis

Additional details on this platform and 3D models can be found by downloading our Hydrogel 3D Tumor Model data sheet for more information, or via this 3D In Vitro Tumor Model scientific poster.

3D tumor models

Predict Anticancer Efficacy with a New In Vitro 3D Modelling Platform

Learn how Cypre’s 3D Tumor Model platform can aid your oncology studies and test therapeutic efficacy in this webinar.

Watch Now


Clonogenic Assay 3D Tumor Models

In the clonogenic assay, patient-derived tumor samples or tumor cell lines are cultured to form ex vivo 3D tumor organoids. Compound effects are then evaluated using image analysis.

Clonogenic Assay 3D Tumor Models

Charles Rivers ex vivo 3D tumor model can be used to screen cancer therapies in vitro, in a range tumor histotypes.

Figure 1: Schematic of ex vivo 3D tumor models in Clonogenic Assay format.

Tumor panel screens in 3D tumor cell culture models with PDX or CDX cell suspensions can be used to assess the efficacy of oncology therapies to inhibit anchorage-independent growth of single cells and ex vivo formation of tumor organoids in single agent of matrix combination layouts. These 3D tumor models can also investigate if anti-tumor activity is selective for different tumor histologies or dependent on molecular markers, allowing therapeutic indication to be determined and indicates candidate tumor models for subsequent in vivo studies.

Download our 3D Tumor Clonogenic Assay Data for more information.


PDX Models and Combination Studies

Data collected in 3D tumor models can then be used to select PDX models for subsequent in vivo efficacy tests. The 3D assay data can also be used to run systematic two-drug combination therapy studies over a range of concentrations and to correlate the tumor response with molecular data (biomarker identification).


Integrating In Vitro and In Vivo PDX Models

Our fully integrated approach using in vitro 2D and ex vivo 3D tumor models, including immune cell mediated tumor killing assays, with in vivo PDX models and bioinformatics data will facilitate drug development and enhance the speed of your oncology research.

microscopic image of breast cancer cells.jpg

Catching Patient Diversity In Vitro: PDX-Based Assays in Oncology Drug Discovery

Discover how scientists are using these 2D and 3D assays to optimize immuno-oncological approaches and see how live-cell imaging and multiplex analysis can help us understand treatment efficacy.

Watch the Webinar

To learn more about our PDX Model offerings, including molecular information, visit our Cancer Model Database, or contact our team to receive expert advice on which assay or model is right for your program.

Ask a Question


Frequently Asked Questions (FAQs) About 3D Tumor Models